Vidutiniai 8 metų gydymo kaštai persirgus ūminiu miokardo infarktu priklausomai nuo rizikos veiksnių ir gretutinių ligų

LTReikšminiai žodžiai: Kaštai; Širdies ir kraujagyslių ligos; Ūminis miokardo infarktas; Acute coronary syndrome; Cardiovascular diseases; Costs.

ENAim. The study shows average cost of treatment in 8 years after acute coronary sindrome (ACS), depending on risk factors, commorbidities and medical history. Matherials and methods. A retrospective cohort longterm study with a total of 613 patiens following ACS 2005- 2013. The mean treatment cost, undoubtedly associated and potentially with ACS associated costs were assessed, depending on sociodemographic factors, past coronary artery disease history, risk factors, commorbidities and ACS complications in 8 years period after ACS. Only cost of the treatment ad diagnostic methods was weighted. The SPSS version 13 was used for the statistical analysis, with a use of descriptive statistics, p level <0,05 considered significant. Results. The mean undoubtedly associated with ACS costs were 11847,83±10745,69 Lt (3431,37±3112,17 €), median 8169,20 Lt (2365,96 €), interquartile rank 11840,96 Lt (3429,38 €). Potentially associated with ACS costs were 1771±4766,05 Lt (512,92±1380,34 €), median 45,92 Lt (13,30 €), interquartile rank 1500 Lt (434,43 €). The significantly highest undoubtedly associated costs were found for people with hypertension and dyslipidaemia, for those with percutaneous coronary intervention or coronary by-pass treatment past history, o for those who were treated with invasive strategy in 8 years after ACS. Also the higher costs were in patients with major cardiovascular events in 8 years ater ACS (p<0,05). Renal failure (p<0,05) and stroke (p<0,001) were factors decreasing undoubtedly associated with ACS costs. Patients with heart failure, coronary by-pass past history, and experienced percutaneous coronary intervention or major cardiovascular event in 8 years after ACS have more higher potentially associated with ACS costs (p<0,05).Conclusion. The study shows the need of good maintenance of hypertension and dyslipidaemia. Likely, the adequate primary and secondary prevention tools should avoid expensive diagnostic and treatment methods and would reduce final ACS costs. [From the publication]